tl;dr – NBOMe mixtures sold as MDMA are around, don’t snort unknown caps, use test-kits wisely, look after your mates, and get your lab student/worker friends to contact us so we don’t need to rely on labs in Barcelona to access high-quality drug testing in Australia!
On the weekend 15-16 January 2017, there was a spate of poisonings, hospitalisations and deaths that have been associated a batch of capsules that were reportedly sold as MDMA or Ecstasy. Punters at Revolver nightclub and other clubs on Melbourne’s Chapel Street were affected.
The contents of these caps appeared damp, more like a brown sugar consistency than crystals or powder.
We obtained anonymous reports from people who consumed these capsules. The reports describe very strong hallucinogenic symptoms and paranoia. While in most cases, the symptoms resolved without medical intervention, they were very unpleasant, with one person reporting that they ‘felt like they were going to die or never be the...
C.J. Hardin, a veteran who served three tours in Iraq and Afghanistan, at a memorial in North Charleston, S.C. He is a patient in the study of MDMA, also known as Ecstasy, as a treatment for post-traumatic stress disorder.
CHARLESTON, S.C. — After three tours in Iraq and Afghanistan, C. J. Hardin wound up hiding from the world in a backwoods cabin in North Carolina. Divorced, alcoholic and at times suicidal, he had tried almost all the accepted treatments for post-traumatic stress disorder: psychotherapy, group therapy and nearly a dozen different medications.
“Nothing worked for me, so I put aside the idea that I could get better,” said Mr. Hardin, 37. “I just pretty much became a hermit in my cabin and never went out.”
Then, in 2013, he joined a small drug trial testing whether PTSD could be treated with MDMA, the...
Please welcome toscablue (Nadine van Gelder) to the Bluelight research assistant position, who will also have a moderating role on Drug Studies.
toscablue will help me liaise with researchers who may wish to donate for banner space or to access our archives for research.
She will also join neversickanymore at Drug Studies: focusing on sorting through all of our research studies, matching older studies up with publications, to illustrate how Bluelight is contributing to research more broadly.
toscablue joins us from Amsterdam - she has held a variety of research assistant roles in the drugs area, most recently working at the EMCDDA, so she has some on-ground drug-research skills to offer.
The Journal of Substance Use recently published a paper which represented the international harm reduction community Bluelight.org as a website used for sourcing drugs.
Yet this article’s conclusions were based only on two case studies, with no attempt to review the existing literature regarding Bluelight. Many in this community would be aware of these studies which show that most people come here to learn how to use drugs more safely, that our members actively disseminate information to warn people of highly dangerous adulterated drugs, and that we regularly collaborate with researchers to provide a leading-edge source of data for monitoring new drug trends. Bluelight is regularly cited as a valued source of harm reduction information for people who use drugs.
Bluelight goes to great lengths to avoid hosting discussions about drug sources. Moderators delete all discussions that could be related to sourcing drugs as quickly as they can.
Researchers from Wright State University (Ohio) have been collaborating with Bluelight (allowing staff to provide feedback on their questionnaire) and supporting Bluelight through a donation to the site.
The study is now closed. Thanks for your support. Results will be posted when complete!
Official advertisement below, for archive purposes:
Wright State University Boonshoft School of Medicine researchers, in collaboration with researchers from Columbia University and the University of Massachusetts, are conducting a survey on cannabis use trends.
This survey is open to all of the Bluelight community, including guest visitors.
To participate in this research study, you need to meet the following requirements:
1) Be 18 years of age or older;
2) Have used cannabis (any form) at least once in your lifetime.
The survey is anonymous - IP addresses will NOT be collected; no identifying information will be asked.
The survey is...
A collaboration between researchers at Karlstad University and Bluelight has resulted in a publication exploring motivations for novel substance use in the International Journal of Drug Policy.
The study was promoted exclusively through Bluelight's banner over a 3 month period. 619 users of novel substances responded to the survey, describing a total of 1551 uses of novel substances (up to 3 per respondent).
We would like to congratulate Christophe Soussan and Professor Anette Kjellgren on their successful publication. We are especially grateful for their decision to make the publication open access, so anyone in our community can read it.
If you are a researcher interested in collaborating with us, please see our Research Portal for more information or contact us directly.
With long-standing excitement, I'd like to announce the creation of a new platform for discussing the rising cultural phenomenon of vaping. Primarily applied to the rising global prevalence of "electronic cigarettes," vaping represents one of the more visible harm reduction hot topics across the world.
The new forum, entitled Vaping Discussion, pertains to all discussion surrounding the science, news, health, culture, safety, hardware, etc. of electronic cigarettes/mods/APVs/ENDS/whatever you'd prefer they be called!
As a special nod to the long-standing practice of vaping as it presents in the communities of our Cannabis-consuming members, the parent forum 'Vaping Discussion' includes a sub-forum within it for all things related to vaping cannabis, and is called Cannabis Vaping Discussion.
Though I'll be spending a great deal of time involving myself with both forums as they start up and begin to expand and evolve, we've appointed two...
We are pleased to announce the appointment of Bluelight's new research assistant - Cameron Norton, from Melbourne, Australia.
Cameron has a background in psychology and languages and has spent most of the past 10 years living in Europe and Asia. Building on a long-standing interest in the field, he recently transitioned into working in one of Melbourne’s largest alcohol and other drug treatment agencies. Cameron is passionate about reducing the stigma attached to substance use and promoting a well-informed and rational discussion about how to make substance use safe and non-destructive. As research assistant he hopes to increase the profile of Bluelight in the research community and improve communication between bluelight users and researchers.
Cameron will be working with me (Monica Barratt) maintaining and growing the research aspects of Bluelight. I'm looking forward to having someone to assist with these tasks as well as to introduce their own ideas about how best to make...
Bluelight is bidding a fond farewell to alasdairm who has decided after many years to step down from heading BL's Admin team. It is no secret that he has contributed more than could possibly be condensed within a single post. Ali has been the role model for generations of BL staff of all levels. His positive energies superseded mere staffing, and indeed his guiding hand and sound thinking stretched to all corners of the community. My personal indebtedness to his character both goes very far and runs very deep.
Bluelight will miss having you in its repertoire. As a community, we can be grateful that you're not leaving the site itself!
Despite Ali's departure, it is with great optimism and gratitude that Bluelight announces its three newest additions to the Administrative Staff!
Please join us in welcoming ebola?, sekio and baooozs to the team!
It's been a short while since Bluelight has had a full-sized team at the administrative level...
BLUELIGHT.ORG: Reducing Harm by Educating the Individual
Bluelight is an international, online harm-reduction community, committed to reducing the harm associated with drug use.
Bluelight neither condones nor condemns the use of drugs. Rather, we accept that drug use will always exist irrespective of legal status or societal norms. While there is no truly safe way to use drugs, we understand that prohibition and abstinence are not realistic or desirable solutions for everyone, nor have they been adequate in addressing the serious public health concerns associated with drug use.
While there is no universal definition of drug-related harm reduction, Bluelight believes that through frank and open discussion we are able to deliver accurate information, eliminate misinformation and empower individuals to make wiser, more responsible choices.
Bluelight understands that drug use encompasses a broad range of behaviors, some safer than others, and that drug use can progress...
Have you ever wondered how Bluelight stays online?
Bluelight co-owners have ensured the survival of the website after our benefactor passed away. There were a few options for us to establish our own revenue streams:
1. Constantly run donation drives (annoying to members, diverts from our focus, extremely time consuming for senior staff, and probably wouldn't be sufficient to pay our bills)
2. Sell advertising to the highest bidder (even more annoying to our members, clutters the site, diverts from our focus)
3. Paid memberships: defeats the purpose of providing harm reduction to the masses and would likely fail, anyway
4. Collaborate with researchers: (May have some hypothetical/theoretical drawbacks, but has many practical benefits, not the least of which includes going Bluelight an opportunity to directly contribute to the growing body of scientific research)
For many reasons we believe the last option provides Bluelight with the most benefit and least...
DENVER, COLO.—On Wednesday, December 17, the Colorado Department of Public Health and Environment awarded a $2 million grant to the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) for their planned study of marijuana for symptoms of posttraumatic stress disorder (PTSD) in 76 U.S. veterans.
Colorado’s Medical Marijuana Scientific Advisory Council recommended that MAPS receive the grant on November 24. Yesterday’s decision followed the Council’s recommendation, giving MAPS the largest of eight grants awarded by CDPHE at Wednesday’s meeting. All of the other grantees are major research universities.
Who exactly is prohibition supposed to be helping? After many years of enforcing drug laws as a police officer, my experience with an addicted family member changed my attitude for good.
I was a police officer for 20 years, enforcing drug laws in California and thinking I was doing my part for society. But what made me think properly about drug use for the first time was my experience with my older brother, Billy. I had watched him struggle with a lifelong problem with drugs. But I still did not understand what it meant to be Billy until my husband convinced me to open up my heart and our home to save him in 2002.
It was in this intimacy of watching Billy try, during the year he lived with us, to live up to the expectations of society and those he loved that I realized that our society’s portrayal of people with chronic drug problems was both damaging and morally flawed.
April 9 at 12:30 am
By Lindsey Bever / The Washington Post - Morning Mix
Please note: bluelight was not affected by this security breach, as we run on a dedicated server with ssl disabled. Thus there is no need to change your password here, however, our intention in posting is to alert you that other sites you frequent might have been endangered.
A newly discovered security bug nicknamed Heartbleed has exposed millions of usernames, passwords and reportedly credit card numbers — a major problem that hackers could have exploited during the more than two years it went undetected.
That’s why some experts were calling Heartbleed the worst bug yet, something that should worry everyone who frequents the Internet or does business on it.
The U.S. Food and Drug Administration today approved a prescription treatment that can be used by family members or caregivers to treat a person known or suspected to have had an opioid overdose. Evzio (naloxone hydrochloride injection) rapidly delivers a single dose of the drug naloxone via a hand-held auto-injector that can be carried in a pocket or stored in a medicine cabinet.
It is intended for the emergency treatment of known or suspected opioid overdose, characterized by decreased breathing or heart rates, or loss of consciousness.
Drug overdose deaths, driven largely by prescription drug overdose deaths, are now the leading cause of injury death in the United States – surpassing motor vehicle crashes. In 2013, the Centers for Disease Control and Prevention reported the number of drug overdose deaths had steadily increased for more than a decade.
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for overdose. However, existing naloxone drugs require administration via syringe and are most commonly used by trained medical personnel in emergency departments and ambulances.
“Overdose and death resulting from misuse and abuse of both prescription and illicit opioids has become a major public health concern in the United States,” said Bob Rappaport, M.D., director of the Division of Anesthesia, Analgesia, and Addiction Products in the FDA’s Center for Drug Evaluation and Research. “Evzio is the first combination drug-device product designed to deliver a dose of naloxone for administration outside of a health care setting. Making this product available could save lives by facilitating earlier use of the drug in emergency situations.”
February 6, 2014 11:35 PM
By Robert Zullo / Pittsburgh Post-Gazette
The war on drugs, Jack Cole said, has been "far worse" than a failure.
Speaking to about 75 students Thursday afternoon at Slippery Rock University, Mr. Cole, a retired New Jersey State Police narcotics detective and a co-founder of Law Enforcement Against Prohibition, called it "a self-perpetuating and constantly expanding policy disaster."
Mr. Cole, who will be speaking in Pittsburgh at noon today at the Rotary Club of Pittsburgh's Northside, 701 N. Point Drive, said 43 years of drug prohibition, millions of arrests and an estimated $1 trillion spent on law enforcement and incarceration have failed to put a dent in drug supplies or their purity, price and rate of use or the explosion in associated crime.
"Once we start treating drug abuse as a health problem instead of a crime problem, we won't have to arrest and sacrifice on the altar of the drug war 1.7 million people a year who we arrest for nonviolent drug offenses, which is what we do today," said Mr. Cole, whose international nonprofit, composed partly of former police officers, prosecutors and judges, supports drug legalization.
He added that the nation's drug policy has also helped to make the United States the world's leader in per capita incarceration, a phenomenon disproportionately affecting blacks.
"The war on drugs has also been the most devastating single destructive social policy since slavery," Mr. Cole said.
Vice magazine recently interviewed bluelight owner, Sebastians_Ghost for as piece on how internet communities are increasingly serving as sources of information for a wide spectrum of drug users: In a World of Opiate Addicts, the Internet Plays Doctor and Therapist
We write to you with something we find uncomfortable to address, but requires your attention nevertheless - yours, mine, everyone's.
In short, Bluelight needs your help. Today.
As Bluelight has grown, so has the need for better servers and bandwidth, improved software, and a proper domain name. In fact, every penny that comes into Bluelight goes right back out in the form of site maintenance (server fees, software and server upgrades).
We've assessed Bluelight's needs and are ready to upgrade our servers with advanced hardware and software capable of supporting us well into the future. However, these upgrades are not cheap and will increase our monthly operating costs. As it stands, Bluelight costs approximately $8000 a year to run before we factor in the upgrades. As mentioned, we run as lean as possible -- no salaries, no personal equipment, no administrative costs whatsoever. We do this so as not to burden the community and to keep Bluelight...